QZQinwen Zuo

Qinwen Zuo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qinwen Zuo has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Binghang Yan

    The Pancreatic Disease Diagnosis and Treatment Center, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China

    1 shared publication
  • Chengxiao Yang

    The Pancreatic Disease Diagnosis and Treatment Center, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China

    1 shared publication
  • Hongze Chen

    Department of Hepatobiliary and Pancreas Surgery, The First Affiliated Hospital of Harbin Medical University

    1 shared publication
  • Jiaming Li

    The Pancreatic Disease Diagnosis and Treatment Center, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China

    1 shared publication
  • Meng Cai

    The Pancreatic Disease Diagnosis and Treatment Center, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China

    1 shared publication
  • Mingkai Cui

    The Pancreatic Disease Diagnosis and Treatment Center, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China

    1 shared publication

Latest Publications

  • Open Access

    RBX1+ CAFs Drives Pancreatic Ductal Adenocarcinoma Progression Through Tenascin C Overexpression

    by Qinwen Zuo, Ziheng Wang, Chengxiao Yang, Binghang Yan, Jiaming Li, Mingkai Cui, Meng Cai, Hongze Chen, Xuewei Bai

    Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense desmoplastic stroma that actively drives malignant progression. However, the specific contributions of E3 ubiquitin ligases within the cancer-associated fibroblast (CAFs) compartment to the PDAC landscape remain largely elusive. Methods: Pancreatic tissue samples were collected from the First Affiliated Hospital of Harbin Medical University. Gene expression was analyzed by RT-PCR, and single-cell RNA sequencing (scRNA-seq) data were integrated for cell subtype identification. Kaplan-Meier survival analysis assessed gene expression and survival. Pseudotime analysis and CellChat evaluated fibroblast transitions and intercellular communication. Cell lines were transfected with RBX1 siRNAs, and protein levels were measured by Western blotting. Proliferation was assessed using colony formation and EdU staining. Statistical analyses were performed using R (v4.4) and GraphPad Prism 8.0. Results: Thirteen E3 ubiquitin ligases were significantly upregulated in PDAC and correlated with unfavorable clinical outcomes. Among these, RBX1 was identified as a candidate preferentially expressed in CAF populations and strongly associated with poor prognosis. Single-cell transcriptomic profiling and pseudotime analysis further revealed that RBX1-positive CAFs were predominantly involved in extracellular matrix remodeling and pro-tumorigenic pathways. Functional assays demonstrated that silencing RBX1 markedly inhibited PAAD cell proliferation and tumor growth both in vitro and in xenograft models. Mechanistically, RBX1 was found to upregulate Tenascin C (TNC) expression, while ectopic overexpression of TNC partially rescued the growth suppression induced by RBX1 knockdown. Conclusions: Our findings suggest that RBX1 facilitates PDAC progression through a CAF-related mechanism and TNC regulation, positioning RBX1 as a potential therapeutic target for PDAC intervention.